The Department of Justice (DOJ) will launch a set of updated rules called the Revised Protocol for the Case Management of ...

The Department of Justice (DOJ) on Thursday launched the revised protocols for the case management of child victims of abuse, neglect, and exploitation, which now also covers discrimination.

Madrigal Pharmaceuticals (NASDAQ:MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical for SYH2086, a new oral GLP-1 receptor agonist being developed as an obesity treatment. As ...

The Department of Justice (DOJ) on Tuesday said it would launch the revised protocol for the case management of child victims ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination therapies for better patient outcomes.

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

CSPC has a very strong financial position. As of 2022, its total debt outstanding is only 1.8% of its total cash in hand. Its annual capital expenditure for 2022 was CNY 1.8 billion. Given its CNY ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

Access CSPC Pharma stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.